Suppr超能文献

移植后绝对淋巴细胞计数作为肝移植后丙型肝炎复发的预测因素。

Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation.

机构信息

Division of Transplant and Hepatobiliary Surgery, Henry Ford Transplant Institute, Henry Ford Hospital, Detroit, MI.

出版信息

Hepatology. 2014 Jan;59(1):35-45. doi: 10.1002/hep.26536. Epub 2013 Aug 7.

Abstract

UNLABELLED

Lymphocytes play an active role in natural immunity against hepatitis C virus (HCV). We hypothesized that a lower absolute lymphocyte count (ALC) may alter HCV outcome after liver transplantation (LT). The aim of this study was to investigate the impact of peritransplant ALC on HCV recurrence following LT. A total of 289 LT patients between 2005 and 2011 were evaluated. Peritransplant ALC (pre-LT, 2-week, and 1-month post-LT) and immunosuppression were analyzed along with recipient and donor factors in order to determine risk factors for HCV recurrence based on METAVIR fibrosis score. When stratifying patients according to pre- and post-LT ALC (<500/μL versus 500-1,000/μL versus >1,000/μL), lymphopenia was significantly associated with higher rates of HCV recurrence with fibrosis (F2-4). Multivariate Cox regression analysis showed posttransplant ALC at 1 month remained an independent predictive factor for recurrence (P = 0.02, hazard ratio [HR] = 2.47 for <500/μL). When peritransplant ALC was persistently low (<500/μL pre-LT, 2-week, and 1-month post-LT), patients were at significant risk of developing early advanced fibrosis secondary to HCV recurrence (F3-4 within 2 years) (P = 0.02, HR = 3.16). Furthermore, severe pretransplant lymphopenia (<500/μL) was an independent prognostic factor for overall survival (P = 0.01, HR = 3.01). The use of rabbit anti-thymocyte globulin induction (RATG) had a remarkable protective effect on HCV recurrence (P = 0.02, HR = 0.6) despite its potential to induce lymphopenia. Subgroup analysis indicated that negative effects of posttransplant lymphopenia at 1 month (<1,000/μL) were significant regardless of RATG use and the protective effects of RATG were independent of posttransplant lymphopenia.

CONCLUSION

Peritransplant ALC is a novel and useful surrogate marker for prediction of HCV recurrence and patient survival. Immunosuppression protocols and peritransplant management should be scrutinized depending on peritransplant ALC.

摘要

目的

研究肝移植(LT)前后绝对淋巴细胞计数(ALC)对丙型肝炎病毒(HCV)复发的影响。

方法

评估了 2005 年至 2011 年间的 289 例 LT 患者。分析了移植前、移植后 2 周和 1 个月的 ALC 和免疫抑制情况,以及受者和供者因素,以根据 METAVIR 纤维化评分确定 HCV 复发的危险因素。根据 LT 前后的 ALC(<500/μL、500-1000/μL 和>1000/μL)对患者进行分层,淋巴细胞减少与纤维化(F2-4)的 HCV 复发率显著相关。多变量 Cox 回归分析显示,移植后 1 个月的 ALC 仍然是复发的独立预测因子(P=0.02,<500/μL 的风险比[HR]为 2.47)。当移植前后的 ALC 持续较低(LT 前<500/μL、移植后 2 周和 1 个月)时,患者发生 HCV 复发导致的早期晚期纤维化(F3-4 在 2 年内)的风险显著增加(P=0.02,HR=3.16)。此外,严重的 LT 前淋巴细胞减少症(<500/μL)是总生存的独立预后因素(P=0.01,HR=3.01)。尽管兔抗胸腺细胞球蛋白诱导(RATG)有潜在的致淋巴细胞减少作用,但它对 HCV 复发有显著的保护作用(P=0.02,HR=0.6)。亚组分析表明,移植后 1 个月时的淋巴细胞减少症(<1000/μL)的负面影响与 RATG 的使用无关,RATG 的保护作用独立于移植后淋巴细胞减少症。

结论

移植前后的 ALC 是预测 HCV 复发和患者生存的一种新的有用的替代标志物。应根据移植前后的 ALC 来仔细检查免疫抑制方案和移植前后的管理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验